Oxidized low-density lipoproteins as a novel risk factor and therapeutic target for ACM

TY - JOUR

T1 - Oxidized low-density lipoproteins as a novel risk factor and therapeutic target for ACM

AU - Tsui, Hoyee

AU - Han, Su Ji

AU - van Rooij, Eva

N1 - © 2021 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2021/9/7

Y1 - 2021/9/7

N2 - Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low-density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro-fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low-density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis.

AB - Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine, Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low-density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro-fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low-density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis.

KW - Arrhythmias, Cardiac

KW - Arrhythmogenic Right Ventricular Dysplasia

KW - Humans

KW - Lipoproteins, LDL

KW - Risk Factors

U2 - 10.15252/emmm.202114789

DO - 10.15252/emmm.202114789

M3 - Article

C2 - 34411432

SN - 1757-4676

VL - 13

SP - e14789

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 9

ER -